Palatin Technologies, Inc. ( NYSE: PTN) Q1 2025 Earnings Conference Call November 14, 2024 11:00 AM ET Carl Spana - CEO and President Stephen Wills - CFO, COO, Treasurer and Secretary ...

Eli Lilly's Phase 3 study shows tirzepatide significantly cuts type 2 diabetes risk and supports 22.9% average weight loss in adults over three years.

Wolfe Research analyst Alexandria Hammond initiated coverage of Johnson & Johnson (JNJ) with an Outperform rating and $190 price target ...

JPMorgan placed shares of Novo Nordisk (NVO) on “Positive Catalyst Watch” ahead of the CagriSema REDEFINE 1 obesity data. The ...

Advent calendars are a fun way to treat yourself or someone else The holiday season is known for some of the best drops in the beauty industry. The shelves (both virtual and real-life) at Sephora ...

EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...

Novo's drugs Ozempic and Wegovy are household names already, and Lilly's Mounjaro and Zepbound are close behind. For the first nine months of 2024, Novo had sales of $29.4 billion, 23% higher than ...

Oral semaglutide: Less common type of semaglutide. Administered either as a tablet or liquid drops, typically in a daily ...

Lilly's newest cash cow, tirzepatide -- a therapy for type 2 diabetes and weight loss that's sold under the names Mounjaro and Zepbound -- is selling a bit slower than anticipated. Though its ...

Last week, Lilly reported that Zepbound sales came in at $1.26 billion in the third quarter, roughly $500 million shy of analyst expectations, although, the company said its weekly prescription ...